Stellantis Down 47% as Rival Surges, But Patient Investors May Have Upside

What happened

Stellantis shares have fallen nearly 47% over the past year, contrasting sharply with a key rival that has gained 47%, reflecting deep investor skepticism over the automaker's turnaround efforts. Weak earnings, dividend cuts, and negative industrial free cash flow have justified the sell-off, but the stock now trades at roughly 2.9x trailing earnings and 0.7x book value, implying significant downside risk is already priced in. The company is executing a capital-intensive $13B U.S. reinvestment and multi-energy platform pivot, though European overcapacity and structural EV price cuts continue to weigh on margins. A permanent CEO appointment and clearer signs of margin and free cash flow recovery in H2 2025 results are necessary catalysts before the stock can re-rate meaningfully. For now, the market remains polarized between a deep-value opportunity and a potential value trap, with execution risk still elevated.

Implication

The risk/reward is asymmetric for patient investors: at ~2.9x earnings and 0.7x book, the stock prices in significant distress. However, the path to recovery is narrow and dependent on flawless execution of the U.S. capacity expansion and European utilization ramp-up. Key catalysts include H2 2025 results due early 2026, the permanent CEO announcement, and the 2026 Capital Markets Day. Until these validate the turnaround thesis, the stock will likely remain discounted. Investors should trim on strength above $14.50 and consider adding near $9.00, maintaining a 6-12 month re-assessment window.

Thesis delta

The market narrative has shifted from primarily a U.S.-share-loss and tariff-vulnerability story to a deeper concern over structural European overcapacity and the sustainability of EV pricing, which pushes recovery timeline out to 2027. While the DeepValue report still sees potential upside, the combination of persistent European headwinds and unproven U.S. reinvestment returns reduces conviction that a near-term re-rating will materialize. The stock's cheapness alone is insufficient to warrant entry without evidence of operational stabilization in both regions.